A pivotal global Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for Niemann-Pick type C1 (NPC1) disease to be highlighted in an oral presentation
GAINESVILLE, Fla.–( BUSINESS WIRE )–Cyclo Therapeutics, Inc . (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease, today announced that its abstracts have been accepted for oral and poster presentation at the 21st Annual WORLDSymposium™ taking place February 3-7, 2025 in San Diego, CA.
The details of the presentations are as follows:
Oral presentation:
Trappsol ® Cyclo™: open-label treatment in the TransportNPC™ substudy in patients younger than 3 years diagnosed with Niemann-Pick type C1 disease
Leader: Ronen Spiegel, Ph.D. med., clinical associate professor, director of the pediatric B department and co-director of the Center for Rare Diseases in Emek Medical (TASE:) Center
Session: Clinical applications
Date and time: Thursday, February 6, 2025 at 1:30 PM PT
Poster presentation:
Trappsol ® Cyclo™ (HPβCD) for the long-term treatment of Niemann-Pick type C1: efficacy and safety data from 4 clinical studies and an ongoing expanded access program
Leader: dr. Caroline Hastings, pediatric hematologic oncologist, director of neuro-oncology and professor of pediatrics at UCSF Benioff Children’s Hospital Oakland
Session: Clinical Applications & Rapid-Fire “ Poster session III
Date and time: Thursday, February 6, 2025 from 3:30 PM to 5:30 PM PT
Trappsol ® Cyclo™ and NPC: Efficacy Demonstrated in Individual 5D Domains and Use of Future Assessment Tools to Demonstrate Clinically Relevant Outcomes
Leader: dr. Caroline Hastings, pediatric hematologic oncologist, director of neuro-oncology and professor of pediatrics at UCSF Benioff Children’s Hospital Oakland
Session: Clinical Applications & Rapid-Fire “ Poster session III
Date and time: Thursday, February 6, 2025 from 3:30 PM to 5:30 PM PT
For more information, visit the conference website at worldsymposia.org.
About WORLDSymposium™
WORLDSymposium™ is an annual research conference dedicated to lysosomal diseases. SVJET is an acronym that stands for the organization of research into lysosomal diseases. Since its inception as a small group of passionate researchers in 2002, WORLDSymposium™ has grown into an international research conference that attracts over 2,000 participants from more than 50 countries around the world. For more information, visit: worldsymposia.org.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with disease. The company’s Trappsol ® Cyclo™, an orphan drug in the United States and Europe, is the subject of four official clinical trials for Niemann-Pick disease type C1, a rare and fatal genetic disease (NCT02939547, NCT02912793, NCT03893071 and NCT04860960). ). The company is conducting a phase 2b clinical trial using Trappsol ® Cyclo™ intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from the Alzheimer’s Disease Expanded Access Program (NCT03624842). Additional indications for the active ingredient in Trappsol ® Cyclo™ are under development. For additional information, visit the Company’s website: www.cyclotherapeutics.com.
Safe harbor statement
This press release contains forward-looking statements about the company’s current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of the closing conditions relating to the offering and the intended use of the proceeds of the offering. Statements that are not historical facts, such as predictions, believes and expects or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from those expressed or implied by these statements. Factors that may affect the Company’s future performance include the Company’s ability to obtain additional capital to expand operations as planned, success in obtaining regulatory approval for clinical protocols, enrolling adequate numbers of patients in clinical trials, unforeseen difficulties in demonstrating the Company’s efficacy of biopharmaceutical products, success in attracting additional customers and profitable contracts and regulatory risks associated with the production of pharmaceutical quality and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Except as required by law, the company undertakes no obligation to update or revise any forward-looking statements as a result of new information or future events.
See the original version on businesswire.com: https://www.businesswire.com/news/home/20250114456775/en/
Contact for investors:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
CYTH@jtsir.com
Source: Cyclo Therapeutics, Inc.
